Separate Moderna, Novavax efforts focusing on combined COVID-19/flu vaccine
Two separate efforts are underway to provide the public with a combination vaccine that would deliver simultaneous protections against COVID-19 and influenza. Moderna today announced its effort during a research-and-development presentation, in which a vaccine would be encoded for the COVID-19 spike protein and flu hemagglutinin glycoproteins. Novavax yesterday said its own effort, which is in a phase 1/2 clinical trial, combines within a single formulation its recombinant protein-based NVX-CoV2373 and NanoFlu vaccine candidates with a patented saponin-based adjuvant.
Related News Articles
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
A CDC study released Dec. 21 found low COVID-19 and flu vaccination coverage for most adults, and low RSV vaccination coverage for adults aged 60 and…
Headline
Fewer than one in four health care professionals working in acute care hospitals and nursing homes were up to date with COVID-19 vaccination during the 2022-23…
Headline
Children under age 12 should receive a 0.25 milliliter dose of the 2023-24 Moderna COVID-19 vaccine, not the full vial for that age group, the Food and Drug…